

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA481)

NICE GUIDANCE ISSUED OCTOBER 2017

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

Use of mycophenolic acid as a sodium salt (Myfortic®) within NHS Wales

Please disseminate the following information to the appropriate individuals within your organisation across NHS Wales.

Dear Colleague

The Minister for Health & Social Services has endorsed AWMSG's recommendation that:

The use of mycophenolic acid as a sodium salt (Myfortic®) should be supported in NHS Wales for the treatment of prophylaxis (in combination with ciclosporin and corticosteroids) of acute rejection in adults receiving allogenic renal transplants, and who are intolerant of mycophenolate mofetil. Its use should be under the supervision of a nephrologist.

If you wish to view the appraisal meeting documentation please click on the link below.

<http://www.wales.nhs.uk/sites3/page.cfm?orgid=371&pid=12428>

This information has been disseminated by the AWMSG Secretariat.

Dr Paul Buss
Acting Chairman AWMSG

9 June 2006

Enquiries: please contact

Mrs Ruth Lang
Liaison Manager
Welsh Medicines Partnership
Dept Pharmacology, Therapeutics & Toxicology
Cardiff University
Wales College of Medicine
Heath Park, Cardiff, CF14 4XN

Tel: 029 20745466

Website address: www.wales.nhs.uk/awmsg/